<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03577652</url>
  </required_header>
  <id_info>
    <org_study_id>20180621</org_study_id>
    <nct_id>NCT03577652</nct_id>
  </id_info>
  <brief_title>The Optimal Strategy of Switching From Clopidogrel to Ticagrelor in Patients With Complexity of Coronary Artery Disease</brief_title>
  <official_title>The Optimal Strategy of Switching From Clopidogrel to Ticagrelor in Patients With Complexity of Coronary Artery Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shenyang Northern Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shenyang Northern Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is to further exploring the optimal switching strategy by evaluating the&#xD;
      pharmacodynamic responses as well as adverse events in patients with complexity of coronary&#xD;
      artery disease managed by percutaneous coronary intervention (PCI). All participants will be&#xD;
      divided into three groups and recieving ticagrelor 90mg plus aspirin 100mg at 12 hours after&#xD;
      the last dose of clopidogrel; recieving ticagrelor 90mg plus aspirin 100mg at 24 hours after&#xD;
      the last dose of clopidogrel; recieving ticagrelor 180mg plus aspirin 100mg at 24 hours after&#xD;
      the last dose of clopidogrel.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 10, 2017</start_date>
  <completion_date type="Actual">January 10, 2018</completion_date>
  <primary_completion_date type="Actual">January 10, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Platelet function assessments</measure>
    <time_frame>7 Days</time_frame>
    <description>The primary endpoint was the comparations between the three projects for the value changes of maximal platelet aggregation (MPA) measured by Light Transmittance Aggregometry (LTA) at 2 hours after switching strategies.</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">108</enrollment>
  <condition>Coronary Artery Disease</condition>
  <condition>Ticagrelor</condition>
  <arm_group>
    <arm_group_label>Ticagrelor, 90mg, 12h</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Ticagrelor, 90mg, 24h</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Ticagrelor, 180mg, 24h</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ticagrelor</intervention_name>
    <description>Ticagrelor, 90mg, 90mg twice daily</description>
    <arm_group_label>Ticagrelor, 180mg, 24h</arm_group_label>
    <arm_group_label>Ticagrelor, 90mg, 12h</arm_group_label>
    <arm_group_label>Ticagrelor, 90mg, 24h</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age between 18-75&#xD;
&#xD;
          2. Patients with complexity of CAD determined by coronary angiography and implanted stent&#xD;
             successfully&#xD;
&#xD;
          3. Taking clopidogrel 75mg daily over 5 days or paients never took clopidogrel previously&#xD;
             should receive 300-600mg drugs at least 12 hours before coronary angiography&#xD;
&#xD;
          4. Agreeing to participate in this trial and signed the written informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. They contraindicated with ticagrelor (including: allergying to ticagrelor or its&#xD;
             active metabolite&#xD;
&#xD;
          2. Concomitanting therapy with a strong cytochrome P-450 3A inhibitor or inducer&#xD;
&#xD;
          3. Previous intracranial haemorrhage or ongoing bleeds&#xD;
&#xD;
          4. Moderate or severe hepatic impairment)&#xD;
&#xD;
          5. Having a previous medication with ticagrelor or long term anticoagulation&#xD;
&#xD;
          6. Having a history of asthma or chronic obstructive pulmonary disease (COPD) and&#xD;
             recurrent attacked&#xD;
&#xD;
          7. Having an uncontrolled hypertension&gt;180/110mmHg&#xD;
&#xD;
          8. Having a hemoglobin&lt;100g/L 9.Having a platelet counts&lt;100Ã—10^9/L&#xD;
&#xD;
          9. Having severe renal impairment (clearance&lt;30mL/min)&#xD;
&#xD;
         10. Having a history of hepaein-induced thrombocytopenia (HIT)&#xD;
&#xD;
         11. Having a pregnancy or were during lactation.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>General Hospital of Shenyang Military Region</name>
      <address>
        <city>Shenyang</city>
        <state>Liaoning</state>
        <zip>110016</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>June 2018</verification_date>
  <study_first_submitted>June 20, 2018</study_first_submitted>
  <study_first_submitted_qc>July 2, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 5, 2018</study_first_posted>
  <last_update_submitted>July 2, 2018</last_update_submitted>
  <last_update_submitted_qc>July 2, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">July 5, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>General Hospital of Shenyang Military Region</investigator_affiliation>
    <investigator_full_name>Han Yaling, MD</investigator_full_name>
    <investigator_title>General Hospital of Shenyang Military Region</investigator_title>
  </responsible_party>
  <keyword>Ticagrelor</keyword>
  <keyword>Clopidogrel</keyword>
  <keyword>Switching strategy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ticagrelor</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

